medigraphic.com
ISSN 0188-2198 (Print)

2005, Number 1

<< Back Next >>

Rev Mex Cardiol 2005; 16 (1)

Treatment

Cardona MEG, Carranza MJ, Hernández HH

Language: Spanish
References: 56
Page: 19-27
PDF size: 63.98 Kb.


Text Extraction

No abstract


REFERENCES

  1. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. Journal of Hypertension 2003; 21: 1011-1053.

  2. He J, Whelton PK. What is the role of dietary sodium and potassium and hypertension and target organ injury? Am J Med Sci 1999; 317: 152-159.

  3. Whelton PK, Appel IJ, Espeland MA. Sodium Reduction and weight loss in the treatment of hypertension in older people: a randomized controlled trial of non-pharmacologic intervention in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279: 839-846.

  4. He J, Whelton PK, Appel IJ. Long-Term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000; 35: 544-549.

  5. Leiter LA, Abbott D, Campbell NRC. A recommendation on obesity and weight loss. CMAJ 1999; 160(Suppl 9): S7-S11.

  6. Stevens VJ, Obarzanek E, Cook NR, Lee IM. Long-term weight loss and changes in results of the Trials of Hypertension Prevention, Phase II. Ann Intern Med 2001; 134: 1-11.

  7. Sacks FM, Svetkey LP, Vollmer WM. For the DASH-Sodium Collaborative Research Group. Effects of blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.

  8. Margwetts BM, Beilin MJ, Vandongen R, Armstrong BK. Vegetarian diet in mild hypertension: a randomized controlled trial. BMJ 1986; 293: 1468-1473.

  9. Hagberg JM, Park JJ, Brown MD. The role of exercise training in the treatment of hypertension: An update Sport Med 2000; 30: 193-206.

  10. Fagard RH. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports and Exerc 2001; 33(Suppl): S484-S492.

  11. Chobanian AV, Hill M. National Heart, Lung and Blood Institute Workshop on Sodium and Blood Pressure: a critical review of current scientific evidence. Hypertension 2000; 35: 858-863.

  12. Volver WM, Sacks FM, Ard J. Effects of diet and sodium intake on blood pressure. Ann Intern Med 2001; 135: 1019-1028.

  13. Xin X, He J, Frontini MG, Ogden LJ. Effects of alcohol reduction on blood pressure. A meta-analysis of randomized controlled trials. Hypertension 2001; 38: 1112-1117.

  14. Hansson L, Zanchetti A, Carruthers SG et al, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principals results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.

  15. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-Stage renal disease in African-american and white men: 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.

  16. Lazarus JM, Bourgoignie JJ, Buckalew VM et al, for the Modification of Diet in Renal Disease Study Group. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29: 641-650.

  17. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type 2 diabetes mellitus: what guidance for recent randomized controlled trials? J Hypertens 2002; 20: 2099-2110.

  18. National Kidney Foundation Guidelines. K/DOQ1 clinical practice guidelines for chronic kidney disease: Kidney Disease Outcomes Quality Initiative. Am J Kidney Dis 2002; 39(Suppl 2): S1-S24.

  19. Hansson L, Zanchetti A. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension. Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755-1762.

  20. World Health Organization. The World Health Report 2002: Risk to Health 2002 Geneva: World Health Organization.

  21. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Death from Cardiovascular Causes, Myocardial infarction, and Stroke in High-Risk Patients. N Engl J of Medicine 2000; 342: 145-153.

  22. Lindholm LH, Ibsen H, Borch-Johnsen K. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.

  23. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T et al. Outcomes with nifedipine GITS or Co-Amilozide in Hypertensive Diabetics and Nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436.

  24. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.

  25. Brown MJ. Implications from hypertension outcome trials for the management of patients with hypertension and diabetes. Br J Diabetes Vasc Dis 2003; 3: 245-251.

  26. Hansson L, Lindholm LH, Niskanen L et al, for the Captopril Prevention Project (CAPPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-616.

  27. Wright JT Jr, Agodoa L, Contreras G. Successful blood pressure control in the african-american Study of Kidney Disease and Hypertension. Arch Intern Med 2002; 162: 1636-1642.

  28. Lewis EJ, Hunsicker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Tipe-2 diabetes. N Engl J Med 2001; 345: 851-860.

  29. Brenner BM, Cooper ME. From the REENAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.

  30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy, Lancet 2000; 355: 253-259.

  31. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with Type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20: 2099-2110.

  32. Marre M, Fernández M, García-Puig J, Halabe A, Hermansen K, Ionescu-Tirgoviste C, Jermendy G et al on behalf of the Investigators; NESTOR Study Group. Value of Natrilix SR in Hypertensive Type 2 diabetics patients with microalbuminuria. J Hypertension 2002; 20(S4): S338.

  33. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.

  34. Flather MD, Yusuf S, Kober L, Pffefer M. Long term ACE-inhibitors therapy in patients with heart failure or left ventricular dysfunction. A systematic overview of data for individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-1581.

  35. Pitt B, Poole-Wilson PA, Segal R. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.

  36. Gottdiener JS, Reda DJ, Massie BM, Matterson BJ, for the Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1997; 95: 2007-2014.

  37. Debereux RV, Palmieri V, Sharpe N. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248-1254.

  38. Cuspide C, Muiesan ML, Valagussa L, on behalf of the CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-2300.

  39. Dahlöf B, Zanchetti A, Diez J, Nicholls MG. Effects of Losartan and Atenolol on left ventricular mass and neurohormonal profile and patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855-1864.

  40. Lindholm LH, Ibsen H, Dahlöf B, Debereux RV. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE). A randomized trial against Atenolol. Lancet 2002; 359: 1004-1010.

  41. Gosse P, Dubourg O, Zannad F et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg the LIVE study. J Hypertens 2000; 18: 1465-1475

  42. Freemantle N, Cleland J, Young P. b-Blockade after myocardial infarction. Systematic review and regression analysis. BMJ 1999; 318: 1730-1737.

  43. Doughty R, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560-565.

  44. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9: 8-16.

  45. The MERIT-HF investigators. Effect of metoprotol CR/XL in chronic heart failure: Metoprotol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.

  46. The CIBIS-II investigators. The Cardiac Insufficiency Bisoprostol Study II. (CIBIS-II): a randomized trial. Lancet 1999; 353: 9-13.

  47. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-90.

  48. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatments in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.

  49. Tuomilehto J, Rastenyte D, Birkenhäger WH et al. For the Systolic Hypertension in Europe Trial Investigators. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999; 340: 677-684.

  50. Staessen J, Wong JG. Benefit of antihypertensive drug treatment in older patients with isolated systolic hypertension. Eur Heart J 1999; Suppl 1(SP): P3-P8.

  51. Emeriau JP, Knauf H, Ocon Pujadas J, Callvo-Gomez C, Abate G, Leonetti G, Chastang C, on behalf of the European Study Investigators. A comparison of indapamida SR 1.5 mg with both amlodipino 5 mg and hydroclorothiazide 25 mg in elderly hypertensive patients a randomized double-blind controlled study. J Hypertens 2001; 19(2): 343-350.

  52. WHO/ISH statement on management of hypertension. J Hypertens 2003; 21: 1983-1992.

  53. Amery A, Birkenhäger WH, Bulpitt CJ, Dollery CT. European Working Party on High blood pressure in the Elderly. Am J Med 1991-90; (Suppl 3): 1S-64S.

  54. Staessen JA, Fagard R, Thijs L et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med 1998; 158: 1681-1691.

  55. Wang JG, Liu G, Wang X, Zhang S, Sun M, Pan X, Jian M, Gong L, Thijs L, Staessen J, Fagard R, Liu L. Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J Hum Hypertens 1996; 10: 735-742.

  56. Leonetti G. Clinical positioning of Indapamide Sustained Release 1.5 mg in Management Protocols for Hypertension. Drugs. 2000; 59(S2): 27-38.




2020     |     www.medigraphic.com